Professor Moon Yonghwa Trains at Mayo Clinic on TIL Therapy and Toxicity Management
Latest Treatment and Patient Safety Systems Applied to CHA-TIL Clinical Trials for Platinum-Resistant Recurrent Ovarian Cancer

Bundang CHA Hospital announced on August 18 that Moon Yonghwa, Professor of Oncology, has completed training in tumor-infiltrating lymphocyte (TIL) immunotherapy systems at the Mayo Clinic in the United States and is applying them to Korea's first TIL clinical trial for ovarian cancer.

Moon Yonghwa, Professor of Oncology at CHA Bundang Medical Center. CHA Bundang Medical Center

Moon Yonghwa, Professor of Oncology at CHA Bundang Medical Center. CHA Bundang Medical Center

View original image

Professor Moon was invited by Professor Arkadiusz Z. Dudek of the Department of Oncology at the Mayo Clinic as a visiting professor, where he observed the clinical operation and toxicity management of TIL therapy, as well as multidisciplinary collaboration systems. He gained hands-on experience with the entire treatment protocol, including patient hospitalization, outpatient follow-up, tissue collection, and TIL infusion for patients undergoing TIL therapy.


In particular, during the high-dose interleukin-2 (IL-2) therapy that follows TIL infusion, he witnessed a multidisciplinary treatment system where oncologists, hematologists, specialized nurses, and clinical pharmacists jointly assess the patient's condition to decide on the necessity of additional doses.


The joint research team of Professor Moon Yonghwa of Bundang CHA Hospital, Professor An Heejeong of the Department of Pathology, and Professor Park Hyun of the Gynecologic Cancer Center is conducting a clinical study targeting patients with platinum-resistant recurrent ovarian cancer using CHA-TIL. CHA-TIL is a TIL cell therapy product where T cells infiltrating the patient's tumor are isolated and cultured to enhance anti-cancer activity before being reintroduced into the patient. Professor Moon plans to apply the treatment protocols and patient safety management systems acquired from this training to the clinical operation of CHA-TIL.



Professor Moon stated, "TIL clinical trials for ovarian cancer are still in the early stages in Korea," and added, "By applying the latest treatment systems in clinical practice, we aim to provide safer and more effective immunotherapy for ovarian cancer patients."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing